Search for content, post, videos
Advertisement

Anocca raises 400 million SEK

The capital injection will be used to further develop the company’s unique process that enables discovery and manufacture of next generation cell therapies for cancer on an industrial scale.

The financing also allows Anocca to progress the company’s first products into clinical trials, it states.

“In recent years, we have made great progress in automating our research platform. In addition, our large-scale and precise analytical methods have allowed us to generate additional data that strengthens the first products that will enter clinical trials. The capital injection will fund the continued expansion of Anocca’s research, development, and manufacturing capabilities as well as the start of a first clinical trial which is planned to be initiated in 2024,” says Reagan Jarvis, CEO of Anocca.

The company operates at the forefront of cancer research and drug development, with its ability to create a broad range of therapies with high precision.”

The financing brings together a solid group of existing and new investors, including Mellby Gård, AMF, Michano, Swedbank Robur, Ramsbury, Nidoco and several well-known family offices and private investors.

“We appreciate the opportunity to invest in such an interesting and important Swedish research company as Anocca. The company operates at the forefront of cancer research and drug development, with its ability to create a broad range of therapies with high precision. They have an impressive capacity and position already today, and very interesting plans for future expansion and development. We look forward to being a part of Anocca’s future growth journey and believe that this will be an investment that will be beneficial for our pension holders, as well as for Sweden, Swedish research, and for patients that will have access to more effective treatments due to Anocca’s breakthrough solutions,” says Anders Oscarsson, Head of Equities at AMF.

The chance to establish a Swedish company as a global leader

Anocca was founded in 2014 and currently has 100 employees. The company’s operations include both research and manufacturing and are located at former AstraZeneca facilities in Södertälje. In recent years, Anocca has focused on automating and expanding its platform to identify the right targets on tumour cells and matching TCRs, while preparing for regulatory approval of the manufacturing facility. Including the current capital raise, Anocca has received a total of SEK 1.3 billion in venture capital. In addition, in December 2022, Anocca was granted a venture debt facility from the European Investment Bank (EIB) of EUR 25 million.

“Anocca’s unique process creates almost endless opportunities to generate new TCR-Ts on a continuous basis. This means that we now have the chance to establish a Swedish company as a global leader in future cancer treatments,” says Hans Stråberg, Chairman of the Board of Anocca.

Photo of Reagan Jarvis, CEO of Anocca

Advertisement